Related Experiment Videos
Adjuvant therapy in melanoma
1Skin Tumour Unit, St John's Institute of Dermatology, St Thomas' Hospital, London, UK.
Abstract:
Melanoma is an immunologic tumour as indicated by clinical regression, long dormancy and the presence of class 1 dependent cytotoxic responses against well defined tumour peptides. The poor prognosis and relative chemoresistance of patients with regional nodal or metastatic disease highlights the urgent need for an effective adjuvant therapy. A wide variety of different agents have been assessed including high dose interferon which has been shown to improve overall survival, although results of a subsequent study have not confirmed these findings. Currently, a variety of different biotherapies and biochemotherapy regimes are being assessed in phase II and III studies and sentinel lymph node biopsy now provides an accurate method for staging so that all patients can be stratified into well-designed randomised controlled trials.
Insights
Melanoma is an immunologic tumor requiring effective adjuvant therapy for advanced stages. Research is exploring various biotherapies and biochemotherapies, alongside improved staging methods, to enhance patient survival and treatment outcomes.
Area of Science:
- Immunology
- Oncology
- Medical Research
Background:
- Melanoma exhibits immunologic characteristics, including clinical regression and dormancy.
- Cytotoxic responses against tumor peptides are present in melanoma.
- Advanced melanoma (regional nodal or metastatic) shows poor prognosis and chemoresistance, necessitating adjuvant therapies.
Purpose of the Study:
- To address the urgent need for effective adjuvant therapy in melanoma.
- To evaluate various therapeutic agents and treatment regimens for melanoma.
- To improve patient stratification for clinical trials through accurate staging.
Main Methods:
- Assessment of diverse therapeutic agents, including high-dose interferon.
- Evaluation of biotherapies and biochemotherapy regimes in phase II and III studies.
- Utilization of sentinel lymph node biopsy for accurate melanoma staging.
Main Results:
- High-dose interferon showed initial promise in improving overall survival, but subsequent studies yielded conflicting results.
- Ongoing phase II and III studies are evaluating various biotherapies and biochemotherapies.
- Sentinel lymph node biopsy enables accurate staging for patient stratification.
Conclusions:
- Despite challenges with some therapies like high-dose interferon, research into biotherapies and biochemotherapies continues.
- Accurate staging via sentinel lymph node biopsy is crucial for stratifying patients into appropriate clinical trials.
- The immunologic nature of melanoma underscores the importance of developing novel adjuvant treatment strategies.